The Effect of Omega-3 Fatty Acid Supplementation on Skeletal Muscle Membrane Composition and Cellular Metabolism
1 other identifier
interventional
24
1 country
1
Brief Summary
The biological membranes that surround a cell and its organelles are vital to the overall function of the cell. Fatty acids are the main structural component of membranes, and the presence of specific fatty acids can alter a membrane's characteristics, which subsequently alters function. Two fatty acids that are of particular interest to researchers are eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). These omega-3 fatty acids have unique unsaturated structures, and their incorporation into biological membranes appear to elicit potent physiological effects. The body is unable to intrinsically synthesize these important fatty acids, so they must be obtained from the diet or through supplementation. Compared to research investigating other body tissues, the effect of EPA and DHA on skeletal muscle membranes and cellular function has received little attention. Of the studies done, EPA and DHA supplementation consistently results in increased EPA, DHA, and total omega-3 fatty acid content in the skeletal muscle membranes of rodents. One study has also demonstrated this effect in humans. These studies, however, have been limited to whole muscle measurements, yet cells contain numerous subcellular membranes with diverse functions. Two membranes of key importance to the metabolic function of a skeletal muscle cell are the membrane that surrounds the cell (plasma membrane), and the membrane that surrounds the mitochondria. The plasma and mitochondrial membranes are responsible for taking up nutrients and converting them into useable energy for the muscle. Recent findings suggest that physiological changes in these processes may occur following EPA and DHA supplementation. At rest and during exercise, there is potential for a shift in substrate selection that favors fat utilization following EPA and DHA supplementation. Several membrane proteins are responsible for transporting fat into the cell and mitochondria. The presence of EPA and DHA within membranes has the potential to affect the membrane integration and function of proteins. The investigators aim to determine whether fat utilization increases following EPA and DHA supplementation, and if there is a concurrent change in the concentrations of fat transport proteins within plasma and mitochondrial membranes. Supplementation with EPA and DHA may also affect oxygen consumption, an important process in energy production that is regulated by mitochondrial membrane proteins. Evidence from human and rodent studies shows a decrease in whole body oxygen consumption following supplementation. The investigators aim to examine these changes directly by measuring mitochondrial respiration following EPA and DHA supplementation. Therefore, the primary purpose of this study is to examine how plasma and mitochondrial membrane fatty acid composition change individually in response to EPA and DHA supplementation in humans. The secondary purpose of this study is to examine functional metabolic changes that occur in skeletal muscle in response to EPA and DHA supplementation, and to investigate correlational relationships between these changes and any compositional alterations in plasma and mitochondrial membranes. The investigators hypothesize that supplementation with EPA and DHA will alter fuel selection at rest and during exercise, and this will correspond to an increase in the concentration of membrane fatty acid transport proteins, and that these changes will correlate to an increase in the EPA, DHA, and total omega-3 content of plasma and mitochondrial membranes.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Nov 2011
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 1, 2011
CompletedFirst Submitted
Initial submission to the registry
November 17, 2012
CompletedFirst Posted
Study publicly available on registry
November 22, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 1, 2013
CompletedStudy Completion
Last participant's last visit for all outcomes
February 1, 2013
CompletedNovember 28, 2012
November 1, 2012
1.3 years
November 17, 2012
November 27, 2012
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Change in skeletal muscle whole muscle membrane fatty acid composition from baseline
Percent change in the content of whole muscle membrane fatty acids
Baseline and 12 weeks
Change in skeletal muscle plasma membrane fatty acid composition from baseline
Percent change in the content of plasma membrane fatty acids
Baseline and 12 weeks
Change in skeletal muscle mitochondrial membrane composition from baseline
Percent change in the content of mitochondrial membrane fatty acids
Baseline and 12 weeks
Secondary Outcomes (4)
Change in whole body resting fat oxidation from baseline
Baseline and 12 weeks
Change in whole body resting carbohydrate oxidation from baseline
Baseline and 12 weeks
Change in whole body sub-maximal exercise fat oxidation from baseline
Baseline and 12 weeks
Change in whole body sub-maximal exercise carbohydrate oxidation from baseline
Baseline and 12 weeks
Other Outcomes (24)
Change in resting heart rate from baseline
Baseline and 12 weeks
Change in sub-maximal exercise heart rate from baseline
Baseline and 12 weeks
Change in sub-maximal exercise blood free fatty acid concentration from baseline
Baseline and 12 weeks
- +21 more other outcomes
Study Arms (2)
Omega-3 Complete
EXPERIMENTALOral ingestion of 3000 mg (5 capsules) of Omega-3 Complete (Jamieson Laboratories Ltd., Windsor, Ontario, Canada) per day for 12 weeks
Placebo Pill
PLACEBO COMPARATOROral ingestion of 5 capsules of a placebo oil pill (Jamieson Laboratories Ltd., Windsor, Ontario, Canada) per day for 12 weeks
Interventions
Eligibility Criteria
You may qualify if:
- Recreationally active
- Must currently practice a consistent diet, and exercise regimen, and maintain this throughout the duration of the study
You may not qualify if:
- Current or previous supplementation with omega-3s
- Average fish intake greater than two times per week
- Sedentary
- Highly active/trained
- Diagnosed respiratory problem
- Diagnosed heart problem/condition
- Lightheadedness, shortness of breath, chest pain, numbness, fatigue, coughing, or wheezing during at rest of with low to moderate physical activity
- Cardiovascular disease risk factors: Family history of heart attacks, hypertension, hypercholesterolemia, diabetes mellitus, smoking, obesity
- Allergies to lidocaine, fish/fish oil, gelatine, glycerin, or mixed tocopherols
- Currently taking any medications or supplements that may increase the chance of bleeding (e.g. Aspirin, Coumadin, Anti-inflammatories, Plavix, Vitamin C or E, high doses of garlic, ginkgo biloba, willow bark products)
- Tendency toward easy bleeding or bruising
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of Guelphlead
- McMaster Universitycollaborator
- Medical University of Bialystokcollaborator
Study Sites (1)
University of Guelph
Guelph, Ontario, N1G 2W1, Canada
Related Publications (6)
Ayre KJ, Hulbert AJ. Dietary fatty acid profile influences the composition of skeletal muscle phospholipids in rats. J Nutr. 1996 Mar;126(3):653-62. doi: 10.1093/jn/126.3.653.
PMID: 8598550BACKGROUNDPeoples GE, McLennan PL. Dietary fish oil reduces skeletal muscle oxygen consumption, provides fatigue resistance and improves contractile recovery in the rat in vivo hindlimb. Br J Nutr. 2010 Dec;104(12):1771-9. doi: 10.1017/S0007114510002928. Epub 2010 Aug 9.
PMID: 20691135BACKGROUNDAndersson A, Nalsen C, Tengblad S, Vessby B. Fatty acid composition of skeletal muscle reflects dietary fat composition in humans. Am J Clin Nutr. 2002 Dec;76(6):1222-9. doi: 10.1093/ajcn/76.6.1222.
PMID: 12450886BACKGROUNDCouet C, Delarue J, Ritz P, Antoine JM, Lamisse F. Effect of dietary fish oil on body fat mass and basal fat oxidation in healthy adults. Int J Obes Relat Metab Disord. 1997 Aug;21(8):637-43. doi: 10.1038/sj.ijo.0800451.
PMID: 15481762BACKGROUNDDelarue J, Labarthe F, Cohen R. Fish-oil supplementation reduces stimulation of plasma glucose fluxes during exercise in untrained males. Br J Nutr. 2003 Oct;90(4):777-86. doi: 10.1079/bjn2003964.
PMID: 13129446BACKGROUNDPeoples GE, McLennan PL, Howe PR, Groeller H. Fish oil reduces heart rate and oxygen consumption during exercise. J Cardiovasc Pharmacol. 2008 Dec;52(6):540-7. doi: 10.1097/FJC.0b013e3181911913.
PMID: 19034030BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Lawrence L Spriet, PhD
University of Guelph
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Purpose
- BASIC SCIENCE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor and Chair
Study Record Dates
First Submitted
November 17, 2012
First Posted
November 22, 2012
Study Start
November 1, 2011
Primary Completion
February 1, 2013
Study Completion
February 1, 2013
Last Updated
November 28, 2012
Record last verified: 2012-11